Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
:CYTK
CYTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.31 - $59.39
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.32M
Market Cap
$4.32B
Enterprise Value$4.61B
Total Cash (Recent Filing)$938.22M
Total Debt (Recent Filing)$791.05M
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Oct 30, 2025EPS Estimate
-1.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding119,427,290
10 Day Avg. Volume1,150,379
30 Day Avg. Volume1,322,292
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue240.13
Enterprise Value/Gross Profit-17.66
Enterprise Value/Ebitda-8.94
Forecast
1Y Price Target
$77.36Price Target Upside113.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyAficamten is believed to provide a differentiated profile relative to Camzyos, with advantages in efficacy, safety, and pharmacology.
Commercial StrategyThe expansion of commercial strategy beyond specialized centers to community cardiology practices is critical as it can tap into significant growth potential.
Regulatory ReviewWith aficamten under regulatory review in the US, EU, and China, these comparative efficacy data could help it strengthen its commercial positioning.
Bears Say
Investor ConcernsConcerns exist regarding a potential increase in adverse events and missed LVEF drops due to the Camzyos label change.
Investor ConfidenceRisks facing CYTK appear well-recognized, but limited conviction exists to support bull case upside scenarios in the near-term.
Market PerformanceCYTK has underperformed in 2025 (-22% YTD vs XBI -4%) as investor expectations have adjusted to aficamten’s label likely containing a REMS similar to Camzyos (mavacamten).
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $59.39 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $4.32B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 30, 2025 which is in 84 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 07, 2025. The company reported -$1.12 earnings per share for the quarter, beating the consensus estimate of -$1.43 by $0.31.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.48.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 119,427,290 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.12 in its last earnings report, beating expectations of -$1.43. Following the earnings report the stock price went down -2.738%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.36 (113.94% Upside)
$77.36 (113.94% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 285.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.32%
12-Months-Change
Fundamentals
Return on Equity
435.49%
Trailing 12-Months
Asset Growth
56.43%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Inc. is a late-stage biopharmaceutical company focused on the discovery and development of muscle biology-driven therapies. The company is primarily engaged in developing small molecule therapeutics to address diseases characterized by muscle dysfunction and weakness. Cytokinetics' core products include drug candidates aimed at treating conditions such as amyotrophic lateral sclerosis (ALS), heart failure, and hypertrophic cardiomyopathy (HCM). By leveraging its expertise in muscle biology and pharmacology, the company aims to transform the treatment landscapes of severe and debilitating diseases.
CYTK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments, such as early trial enrollment completion and strong financial positioning, countered by delays in drug approval and increased expenses. The sentiment is balanced with notable achievements and challenges.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$77.36
▲(113.94% Upside)
Technical Analysis
Ownership Overview
0.80% Insiders
36.74% Mutual Funds
0.48% Other Institutional Investors
37.92% Public Companies and Individual Investors